
K_{ν} 7-type Channel Currents in Spiral Ganglia Neurons: Involvement in Sensorineural Hearing Loss

Ping Lv, Dongguang Wei and Ebenezer N. Yamoah

Supplementary Figure 1 (S1)

Effects of linopirdine under reduced extracellular Ca^{2+} conditions. Upper and second panels show apical (A) and basal (B) SGNs in culture with BDNF/NT3 growth factors and reduced bath Ca^{2+} (~300 μ M). The third and fourth row shows apical (A) and basal SGNs in the presence of 10 μ M linopirdine and a cocktail of Ca^{2+} channel blockers. TUJ1 = neuronal maker, Apop (apoptosis = TUNEL- positive, DAPI= nuclei stain).

Supplementary figure 1 (S1)



Supplementary Table S1-8

Table S1

Changes in action potential waveforms at different ages

Apex	2 week old	3-4 month old (n	17 month old (n
	(n = 11)	= 12)	= 9)
Rmp (mV)	-63 ± 4	-65 ± 2	-60 ± 3#
Threshold (mV)	-44 <u>+</u> 3	-39 ± 2**	-35 ± 2**##
AP (duration) (ms)	8 ± 2	8 ± 2 $6 \pm 1**$	
Latency (ms)	5 ± 1	3 ± 0**	4 ± 1*
Max depolarization. slope			
(mV/ms)	104 ± 38	136 ± 26	118 ± 20
Max repolarization slope			
(mV/ms)	-54 ± 18	-75 ± 16*	-68 ± 15
Half width (ms)	0.5 ± 0.2	0.5 ± 0.1	0.6 ± 0.1

^{**}p<0.01, *p<0.05 vs 2 week

#p<0.01,#p<0.05 vs 3-4 month

Table S2

Base	2 week (0.5 months)	3-4 month old (n	17 month old (n	
	old $(n = 9)$	= 7)	= 7)	
Rmp (mV)	-57 ± 2	-60 ± 4	-54 ± 3*#	
Threshold (mV)	-40 ± 2	-38 ± 1	-35 ± 3.0** #	
Spike number	43 ± 10	18 ± 5**	34 ± 7*##	
AP duration (ms)	6 ± 1	$8\pm2*$	8 ± 1**	
Latency (ms)	4 ± 1	6 ± 1*	5 ± 1*	
Max depolarization slope				
(mV/ms)	177 ± 40	164 ± 36	129 ± 17*#	
Max repolarization slope				
(mV/ms)	-123 ± 26	-107 ± 26	-90 ± 21*	
Half Width (ms)	0.6 ± 0.1 0.7 ± 0.1		$0.7 \pm 0.2*$	

^{**}p<0.01, *p<0.05 versus 2 week

##p<0.01, # p<0.05 versus 3-4 month

Table S3

The effect of linopirdine on action potentials

2 week (0.5 month) old mice	Base (n = 11)		Apex (n = 12)	
-	Linopirdine			Linopirdine
	Control	(10 μM)	Control	(10 μM)
Spike number	40 ± 13	47 ± 6	1 ± 0	1 ± 0
Rmp (mV)	-62 ± 3	-53 ± 3*	-63 ± 4	-57 ± 3
Threshold(mV)	-39 ± 3	-38 ± 3	-43 ± 3	-43 ± 2
AP duration (ms)	7 ± 1	6 ± 1	9 ± 2	7 ± 1
Latency (ms)	5 ± 1	4 ± 1*	5 ± 1	4 ± 1*
Max depolarization slope				
(mV/ms)	180 ± 48	156 ± 55	105 ± 42	95 ± 12
Max repolarization slope				
(mV/ms)	-125 ± 36	-105 ± 40	-52 ± 19	-49 ± 8
Half width (ms)	0.6 ± 0.1	0.66 ± 0.2	0.55 ± 0.1	0.61 ± 0.1

^{*}p<0.05, **p<0.01 Treatment versus control

Table S4

3-4 month old mice					
	Base $(n = 9)$		Apex $(n = 8)$		
_		Linopirdine		Linopirdine (10	
	Control	(10 μM)	Control	μ M)	
Spike number	19 ± 5	40 ± 7 **	1 ± 0	1 ± 0	
Rmp (mV)	-57 ± 4	-51 ± 3*	-63 ± 4	-60 ± 4	
Threshold (mV)	-40 ± 2	-39 ± 3	-39 ± 2	-37 ± 4	
AP duration (ms)	8 ± 2	7 ± 2	6 ± 1	6 ± 1	
Latency (ms)	5 ± 2	5 ± 1	3 ± 0	3 ± 0	
Max depolarization slope					
(mV/ms)	182 ± 46	119 ± 49	136 ± 26	79 ± 26**	
Max repolarization slope					
(mV/ms)	-121 ± 39	-79 ± 32	-75 ± 16	-45 ± 16**	
Half width (ms)	0.6 ± 0.2	0.7 ± 0.3	0.5 ± 0.1	0.6 ± 0.2	

^{*}p<0.05, **p<0.01 Treatment *versus* control

Table S5

17 month old mice	Base (n = 5)		Aŗ	pex (n = 6)
_	Linopirdine			Linopirdine (10
	Control	(10 μM)	Control	μ M)
Spike number	22 ± 7	38 ± 7 **	1 ± 0	1 ± 0
Rmp (mV)	-54 ± 4	-44 ± 4*	-60 ± 4	-60 ± 4
Threshold (mV)	-37 ± 4	-35 ± 5	-36 ± 2	-34 ± 4
AP duration (ms)	7 ±0	6 ± 2	6 ± 1	6 ± 1
Latency (ms)	5 ± 1	4 ± 2	4 ± 0	3 ± 0
Max depolarization slope				
(mV/ms)	134 ± 13	177 ± 46	139 ± 26	$82\pm26*$
Max repolarization slope				
(mV/ms)	-99 ± 8	-129 ± 40	-89 ± 16	-65 ± 16*
Half width (ms)	0.6 ± 0	0.6 ± 0	0.5 ± 0.1	0.6 ± 0.2

^{*}p<0.05, **p<0.01 Treatment *versus* control

Table S6

The effect of retigabine on action potentials

2 week (0.5 month) old

mice

	Base $(n = 4)$		Apex $(n = 5)$	
_	Retigabine (10		Retigabine	
	Control	μ M)	Control	(10 μM)
Spike number	29 ± 12	2 ± 1	1 ± 0	0**
Rmp (mV)	-58 ± 2	-64 ± 1*	-66 ± 4	-75 ± 5*
Threshold (mV)	-40 ± 2	-40 <u>+</u> 1	-39 ± 3	-
AP duration (ms)	7 ± 1	6 <u>+</u> 3	6 ± 2	-
Latency (ms)	4 ± 0	-	4 ± 1	-
Max depolarization slope				
(mV/ms)	166 ± 33	-	131 ± 109	-
Max repolarization slope				
(mV/ms)	-104 ± 41	-	-85 ± 42	-
Half width (ms)	0.7 ± 0.2	-	0.6 ± 0.2	-

^{*}p<0.05, **p<0.01 Treatment versus control

Table S7

3-4 month old mice

	Base $(n = 7)$		Apex $(n = 8)$	
_	Retigabine (10			Retigabine (10
	Control	μ M)	Control	μΜ)
Spike number	20 ± 6	$0.4 \pm 0.5**$	1 ± 0	0**
Rmp (mV)	-59 ± 3	-66 ± 3 *	-62 ± 2	-66 ± 3
Threshold (mV)	-37 ± 3	-	-42 ± 3	-
AP duration (ms)	8 ± 2	-	8 ± 1	-
Latency (ms)	5 ± 2	-	6 ± 2	-
Max depolarization.				
Slope (mV/ms)	152 ± 37	-	125 ± 31	-
Max repolarization slope				
(mV/ms)	-94 ± 27	-	-71 ± 39	-
Half Width (ms)	0.7 ± 0.2	-	0.8 ± 0.5	-

^{*}p<0.05, **p<0.01 Treatment versus control

Table S8

17 month old mice

	Base $(n = 5)$		Apex $(n = 6)$	
-	Retigabine (10			Retigabine (10
	Control	μ M)	Control	μΜ)
Spike number	22 ± 6	1 ± 1**	1 ± 0	0**
Rmp (mV)	-59 ± 3	-69 ± 2 *	-61 ± 2	-67 ± 2*
Threshold (mV)	-37 ± 3	-	-42 ± 3	-
AP duration (ms)	6 ± 2	-	7 ± 1	-
Latency (ms)	3 ± 1	-	5 ± 2	-
Max depolarization.				
Slope (mV/ms)	89 ± 37	-	125 ± 31	-
Max repolarization slope				
(mV/ms)	-93 ± 17	-	-71 ± 39	-
Half Width (ms)	0.4 ± 0.2	-	0.5 ± 0.2	-

^{*}p<0.05, **p<0.01 Treatment versus control